Workflow
Xencor (XNCR) Update / Briefing Transcript
XencorXencor(US:XNCR)2025-04-29 21:00

Summary of Xencor (XNCR) Update / Briefing April 29, 2025 Company Overview - Company: Xencor (XNCR) - Focus: Development of protein engineering and drug molecules for unmet medical needs, particularly in oncology and immunology Key Industry Insights - Industry: Inflammatory Bowel Disease (IBD) treatment - Current Market Need: High unmet medical need in IBD, with existing medications achieving remission in only 10% to 20% of patients [7][8] - Target Population: Over 3 million individuals affected by IBD in the U.S. and Europe [7] Core Program Updates - XmAb942: A high potency, half-life extended anti-TL1A antibody - Phase I Study Results: Positive interim results indicating safety and pharmacokinetics [2][12] - Half-Life: Estimated at greater than 71 days, promising for convenient dosing [14] - Dosing Schedule: Planned Q12 week subcutaneous maintenance dosing [11][21] - TL1A by IL-23 P19 Bispecific: A lead candidate designed to combine two effective mechanisms of action for IBD treatment - Development Timeline: First in human studies expected in 2026 [58] Clinical Development Plans - Phase II Study (ZENITH UC): - Focus on patients with moderately to severely active ulcerative colitis who have failed previous therapies [19][21] - Primary endpoint: Clinical remission based on modified Mayo Score at week twelve [21] - Expected to start in the second half of 2025 [61] Competitive Landscape - Comparison with Competitors: XmAb942 expected to provide higher drug exposure and better clinical outcomes compared to leading first-generation anti-TL1A drugs [60] - Dosing Frequency: Over 90% of surveyed gastroenterologists believe that XmAb942's Q12 week dosing could significantly improve patient compliance [61] Future Directions - Combination Therapies: Emphasis on developing a combination strategy with IL-23 and TL1A targeting to enhance efficacy [49][54] - Market Positioning: Xencor aims to position XmAb942 as a first or second line treatment option in advanced IBD therapy [60] Important Considerations - Safety Profile: No significant safety signals observed in Phase II data for competing therapies [31] - Patient Compliance: A more convenient dosing schedule is expected to improve patient quality of life and adherence to treatment [42][43] Conclusion - Xencor is advancing its pipeline with promising data for XmAb942 and a bispecific candidate targeting TL1A and IL-23, aiming to address significant unmet needs in IBD treatment while enhancing patient experience through improved dosing regimens and safety profiles [66]